Davis Polk advised ShockWave Medical, Inc. on its SEC-registered initial public offering of 6,555,000 shares of common stock for an aggregate price to the public of approximately $111.4 million, including 855,000 shares sold pursuant to the underwriters’ option to purchase additional shares. The shares are listed on the NASDAQ Global Select Market under the symbol “SWAV.”
Headquartered in Santa Clara, California, ShockWave Medical, Inc. is a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. ShockWave Medical aims to establish a new standard of care for medical device treatment of atherosclerotic cardiovascular disease through its differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque.
The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jason Bassetti and associates Stephanie Y. Cheng and Blake Anderson. The intellectual property and technology team included partner David R. Bauer and associates Jay Frankel and S. Dream Montgomery. Partner Rachel D. Kleinberg and associate Joseph M. Gerstel provided tax advice. Counsel Gregory D. Hughes provided executive compensation advice. Members of the Davis Polk team are based in the Northern California and New York offices.